- Home
- FLZH vs XRTX Comparison
FLZH vs XRTX Comparison
Compare FLZH & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FLZH | XRTX |
|---|---|---|
| Founded | N/A | 2011 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1M | 4.3M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | FLZH | XRTX |
|---|---|---|
| Price | $1.86 | $2.05 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 131.6K | 9.0K |
| Earning Date | N/A | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.60 | $0.35 |
| 52 Week High | $2.88 | $3.60 |
Technical Indicators
Market Signals| Indicator | FLZH | XRTX |
|---|---|---|
| Relative Strength Index (RSI) | 21.57 | 43.36 |
| Support Level | $1.61 | $2.02 |
| Resistance Level | $1.91 | $2.28 |
| Average True Range (ATR) | 0.24 | 0.11 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 21.95 | 28.12 |
Price Performance
Historical ComparisonAbout XRTX XORTX Therapeutics Inc.
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.